{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:15:22Z","timestamp":1782515722556,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lundbeck LLC, Deerfield, IL, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"Abstract<\/jats:title>\n Background<\/jats:title>\n Migraine is a disabling neurologic disease that can fluctuate over time in severity, frequency, and acute medication use. Harris Poll Migraine Report Card was a US population-based survey to ascertain quantifiable distinctions amongst individuals with current versus previous high-frequency headache\/migraine and acute medication overuse (HFM+AMO). The objective of this report is to compare self-reported experiences in the migraine journey of adults with HFM+AMO to those who previously experienced HFM+AMO but currently have a sustained reduction in headache\/migraine frequency and acute medication use.<\/jats:p>\n <\/jats:sec>\n Methods<\/jats:title>\n An online survey was available to a general population panel of adults (\u226518 years) with migraine per the ID Migraine\u2122 screener. Respondents were classified into \u201ccurrent HFM+AMO\u201d (within the last few months had \u22658 headache days\/month and \u226510 days\/month of acute medication use; n<\/jats:italic>=440) or \u201cprevious HFM+AMO\u201d (previously had HFM+AMO, but within the last few months had \u22647 headache days\/month and \u22649 days\/month of acute medication use; n<\/jats:italic>=110). Survey questions pertained to demographics, diagnosis, living with migraine, healthcare provider (HCP) communication, and treatment.<\/jats:p>\n <\/jats:sec>\n Results<\/jats:title>\n Participants in the current HFM+AMO group had 15.2 monthly headache days and 17.4 days of monthly acute medication use in last few months compared to 4.2 and 4.1 days for the previous HFM+AMO group, respectively. Overall, current preventive pharmacologic treatment use was low (15-16%; P<\/jats:italic>>0.1 for current vs previous) in both groups. Previous HFM+AMO respondents reported better current acute treatment optimization. More respondents with current (80%) than previous HFM+AMO (66%) expressed concern with their current health (P<\/jats:italic><0.05). More than one-third of both groups wished their HCP better understood their mental\/emotional health (current 37%, previous 35%; P<\/jats:italic>>0.1 for current vs previous) and 47% (current) to 54% (previous) of respondents worried about asking their HCP too many questions (P<\/jats:italic>>0.1 for current vs previous).<\/jats:p>\n <\/jats:sec>\n Conclusion<\/jats:title>\n Apart from optimization of acute medication, medical interventions did not significantly differentiate between the current and previous HFM+AMO groups. Use of preventive pharmacological medication was low in both groups. Adults with current HFM+AMO more often had health concerns, yet both groups expressed concerns of disease burden. Optimization of acute and preventive medication and addressing mental\/emotional health concerns of patients are areas where migraine care may impact outcomes regardless of their disease burden.<\/jats:p>\n <\/jats:sec>\n Graphical Abstract<\/jats:title>\n \n <\/jats:sec>","DOI":"10.1186\/s10194-024-01725-2","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T09:03:40Z","timestamp":1708938220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Harris Poll Migraine Report Card: population-based examination of high-frequency headache\/migraine and acute medication overuse"],"prefix":"10.1186","volume":"25","author":[{"given":"Amaal J.","family":"Starling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Buzby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Spinale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Lenaburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kymes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"issue":"19","key":"1725_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Engl J Med 383(19):1866\u201376. https:\/\/doi.org\/10.1056\/NEJMra1915327","journal-title":"N Engl J Med"},{"issue":"1","key":"1725_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain"},{"issue":"9","key":"1725_CR3","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML et al (2018) Migraine in America Symptoms and Treatment (MAST) Study: baseline study methods, treatment patterns, and gender differences. Headache 58(9):1408\u201326. https:\/\/doi.org\/10.1111\/head.13407","journal-title":"Headache"},{"issue":"5","key":"1725_CR4","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.mayocp.2016.02.013","volume":"91","author":"DC Buse","year":"2016","unstructured":"Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A et al (2016) Impact of migraine on the family: perspectives of people with migraine and their spouse\/domestic partner in the CaMEO study. Mayo Clin Proc 91(5):596\u2013611. https:\/\/doi.org\/10.1016\/j.mayocp.2016.02.013","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"1725_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM et al (2019) Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59(8):1286\u201399. https:\/\/doi.org\/10.1111\/head.13613","journal-title":"Headache"},{"issue":"1","key":"1725_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","volume":"21","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ et al (2020) Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain 21(1):23. https:\/\/doi.org\/10.1186\/s10194-020-1084-y","journal-title":"J Headache Pain"},{"issue":"1","key":"1725_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10194-018-0865-z","volume":"19","author":"TJ Schwedt","year":"2018","unstructured":"Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC et al (2018) Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain 19(1):38. https:\/\/doi.org\/10.1186\/s10194-018-0865-z","journal-title":"J Headache Pain"},{"issue":"3","key":"1725_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/cpj.0000000000001037","volume":"11","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ, Buse DC, Argoff CE, Reed ML, Fanning KM, Hussar CR et al (2021) Medication overuse and headache burden: results from the CaMEO study. Neurol Clin Pract 11(3):216\u201326. https:\/\/doi.org\/10.1212\/cpj.0000000000001037","journal-title":"Neurol Clin Pract"},{"issue":"7","key":"1725_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0333102414552532","volume":"35","author":"AM Adams","year":"2015","unstructured":"Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM et al (2015) The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia 35(7):563\u201378. https:\/\/doi.org\/10.1177\/0333102414552532","journal-title":"Cephalalgia"},{"issue":"8","key":"1725_CR10","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/head.12878","volume":"56","author":"RB Lipton","year":"2016","unstructured":"Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML (2016) A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: demographics and headache-related disability. Headache 56(8):1280\u20139. https:\/\/doi.org\/10.1111\/head.12878","journal-title":"Headache"},{"issue":"11","key":"1725_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11916-021-00982-z","volume":"25","author":"SK Parikh","year":"2021","unstructured":"Parikh SK, Kempner J, Young WB (2021) Stigma and migraine: developing effective interventions. Curr Pain Headache Rep 25(11):75. https:\/\/doi.org\/10.1007\/s11916-021-00982-z","journal-title":"Curr Pain Headache Rep"},{"key":"1725_CR12","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 38(1):1-211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"issue":"S1","key":"1725_CR13","first-page":"33","volume":"62","author":"F Cohen","year":"2022","unstructured":"Cohen F, Brooks CV, Sun DM, Reed ML, Buse DC, Lipton RB (2022) Migraine prevalence has remained stable while disability has increased in US population studies. Headache 62(S1):33\u20134","journal-title":"Headache"},{"issue":"10283","key":"1725_CR14","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/s0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A et al (2021) Migraine: epidemiology and systems of care. Lancet 397(10283):1485\u201395. https:\/\/doi.org\/10.1016\/s0140-6736(20)32160-7","journal-title":"Lancet"},{"issue":"5","key":"1725_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000252808.97649.21","journal-title":"Neurology"},{"key":"1725_CR16","doi-asserted-by":"publisher","unstructured":"Ailani J, Burch RC, Robbins MS, on behalf of the Board of Directors of the American Headache Society (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 61(7):1021-39. https:\/\/doi.org\/10.1111\/head.14153.","DOI":"10.1111\/head.14153"},{"issue":"7","key":"1725_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/head.14170","volume":"61","author":"R Ishii","year":"2021","unstructured":"Ishii R (2021) Should chronic migraine be defined by eight or more headache days per month? Headache 61(7):983\u20134. https:\/\/doi.org\/10.1111\/head.14170","journal-title":"Headache"},{"key":"1725_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/head.13966","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB (2020) Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. https:\/\/doi.org\/10.1111\/head.13966","journal-title":"Headache"},{"issue":"3","key":"1725_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1212\/01.wnl.0000078940.53438.83","volume":"61","author":"RB Lipton","year":"2003","unstructured":"Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J et al (2003) A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 61(3):375\u201382. https:\/\/doi.org\/10.1212\/01.wnl.0000078940.53438.83","journal-title":"Neurology"},{"issue":"7","key":"1725_CR20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1468-2982.2008.01786.x","volume":"29","author":"RB Lipton","year":"2009","unstructured":"Lipton RB, Kolodner K, Bigal ME, Valade D, Lainez MJ, Pascual J et al (2009) Validity and reliability of the Migraine-Treatment Optimization Questionnaire. Cephalalgia 29(7):751\u20139. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01786.x","journal-title":"Cephalalgia"},{"issue":"7","key":"1725_CR21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/wnl.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC (2015) Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84(7):688\u201395. https:\/\/doi.org\/10.1212\/wnl.0000000000001256","journal-title":"Neurology"},{"issue":"3","key":"1725_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A et al (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 31(3):301\u201315. https:\/\/doi.org\/10.1177\/0333102410381145","journal-title":"Cephalalgia"},{"issue":"2","key":"1725_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/head.14259","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Nicholson RA, Reed ML, Araujo AB, Jaffe DH, Faries DE et al (2022) Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study. Headache 62(2):122\u201340. https:\/\/doi.org\/10.1111\/head.14259","journal-title":"Headache"},{"issue":"10","key":"1725_CR24","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC et al (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 52(10):1456\u201370. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02223.x","journal-title":"Headache"},{"issue":"24","key":"1725_CR25","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1212\/wnl.0000000000004025","volume":"88","author":"A Saadi","year":"2017","unstructured":"Saadi A, Himmelstein DU, Woolhandler S, Mejia NI (2017) Racial disparities in neurologic health care access and utilization in the United States. Neurology 88(24):2268\u201375. https:\/\/doi.org\/10.1212\/wnl.0000000000004025","journal-title":"Neurology"},{"issue":"3","key":"1725_CR26","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1111\/1475-6773.12705","volume":"53","author":"JI Manuel","year":"2018","unstructured":"Manuel JI (2018) Racial\/ethnic and gender disparities in health care use and access. Health Serv Res 53(3):1407\u201329. https:\/\/doi.org\/10.1111\/1475-6773.12705","journal-title":"Health Serv Res"},{"issue":"8","key":"1725_CR27","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s11606-008-0591-3","volume":"23","author":"RB Lipton","year":"2008","unstructured":"Lipton RB, Hahn SR, Cady RK, Brandes JL, Simons SE, Bain PA et al (2008) In-office discussions of migraine: results from the American Migraine Communication Study. J Gen Intern Med 23(8):1145\u201351. https:\/\/doi.org\/10.1007\/s11606-008-0591-3","journal-title":"J Gen Intern Med"},{"key":"1725_CR28","doi-asserted-by":"publisher","unstructured":"Torres-Ferr\u00fas M, Ursitti F, Alpuente A, Brunello F, Chiappino D, de Vries T, et al. (2020) From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain 21(1):42-. https:\/\/doi.org\/10.1186\/s10194-020-01111-8.","DOI":"10.1186\/s10194-020-01111-8"},{"issue":"22","key":"1725_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3238\/arztebl.2018.0365","volume":"115","author":"HC Diener","year":"2018","unstructured":"Diener HC, Holle D, Dresler T, Gaul C (2018) Chronic headache due to overuse of analgesics and anti-migraine agents. Deutsches Arzteblatt Int 115(22):365\u201370. https:\/\/doi.org\/10.3238\/arztebl.2018.0365","journal-title":"Deutsches Arzteblatt Int"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01725-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T09:03:46Z","timestamp":1708938226000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01725-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1725"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01725-2","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"3 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AJS has received consulting fees from AbbVie, Allergan, Amgen, Axsome Therapeutics, Everyday Health, Lundbeck, Med-IQ, Medscape, Neurolief, Satsuma, and WebMD. RC was an employee of Lundbeck LLC for the development and initiation of the survey and currently consults with Biohaven, Haleon, Lundbeck, and is a part time employee at Axon. DCB has received grant support from the US Food and Drug Administration, and the National Headache Foundation; served as a consultant and received honoraria from Allergan, Amgen\/Novartis, Biohaven, Collegium, Eli Lilly, Lundbeck, and Teva; and served on the editorial board of Current Pain and Headache Reports.<\/i> MB is an employee of the Coalition for Headache and Migraine Patients (CHAMP), an organization that receives sponsorship support from AbbVie, Amgen, Impel, Lilly, Lundbeck, and Teva. CS and KS are employees of The Harris Poll, a company that received funding from Lundbeck LLC for time spent conducting this research. KL has received consulting fees from AbbVie, Allergan, Impel, and Lundbeck; during the development and fielding of the survey. KL was an employee of the Coalition for Headache and Migraine Patients (CHAMP), an organization that receives sponsorship support from AbbVie, Amgen, Impel, Lilly, Lundbeck, and Teva. SK was an employee of Lundbeck LLC for the development and completion of the survey.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}